English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduRucaparib is in a relatively new class of drugs – Poly(ADP-ribose) polymerase or PARP inhibitors – which have been approved for therapy in ovarian cancers. This study provides insights into both how the cancers resist treatments, and which patients may respond favorably to the drug.
Tag: ovarian cancer research
UK, ArtemiLife Partner to Test for Anti-Cancer Activity of Artemisia Annua Extracts
The University of Kentucky and ArtemiLife Inc. will collaborate on a clinical study using the extract of a medicinal plant grown in Kentucky to test for anti-cancer activity of Artemisia annua and to determine the recommended dose of Artemisia annua for future clinical trials.
NCCN Announces Projects to Improve Ovarian Cancer Care, with AstraZeneca
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announces four projects selected to receive support directed towards improving the quality of care for advanced ovarian cancer patients, funded through a collaboration with AstraZeneca.